IMMUNOGENIK, INC.

Biotech · Private

Antibody therapeutic targeting LAIR1 to block tumor-associated macrophage immunosuppression

Grants
$798K
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Advancing cancer therapy: Developing antibody blockade targeting a novel immune checkpoint, LAIR1/CD305$398,997
Federal grantDepartment of Health and Human Services · Phase I · Enhance Cancer Therapeutics with 3-in-1 CAR T Cells$398,997
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2727Metaphore Biotechnologies——
2728Cellarity——
2729VAXSYNA, INC.——
2730IMMUNOGENIK, INC.——
2731EPIGENTER, LLC——
2732OMETA LABS LLC——
2733IMAGEN BIOWORKS INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.